InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: Alexxdj1 post# 668

Wednesday, 01/01/2020 12:08:13 PM

Wednesday, January 01, 2020 12:08:13 PM

Post# of 977
Well Morgan Stanley just bought more the other day I think they have about 1.67 million shares now if I read the filing correctly. Anyways, I TRIL as being good and maybe even better than FTSV. That's because TRIL has 3 anti-CD47 products in its pipeline. One uses IgG1 , then the 2nd uses IgG4 extension (FTSV only uses this one) and then a 3rd undisclosed anti-CD47 product in preclinical. That doesn't even account for the other products like the immuno-oncology in preclinical and the second generation STING Product It all looks good IMO but we need to see the next set of data using the higher than 0.5 mg/kg dose. They said they were able to get the dose higher so it's important to see it. The good news is that going from 0.2 mg/kg to 0.5 mg/kg has kept thrombocytopenia side effect at 18%. That risk didn't increase on higher dose. If the same thing happens with higher doses this is golden.